New York, July 17, 2024 - PRISM MarketView - Australian biotechnology company, Immuron Limited (Nasdaq: IMRN), has achieved record sales of its over-the-counter immune supplement, Travelan®, an orally administered immunotherapy that reduces the likelihood of contracting Travelers’ Diarrhea, a digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce.
The company achieved a new annual sales record in the United States, increasing by 74% to AUD $1.1 million for the full financial year to June 2024 (FY24), while Australian sales of Travelan® increased 236% to AUD $3.7 million for the full financial year to June 2024 (FY24).
“We continue to be excited by the strong sales results on Travelan®. Immuron’s investment to drive awareness of the Travelan® brand has seen continued strong sales results in Australia. We were incredibly pleased to achieve record U.S. sales in FY24. We hope to achieve strong North American growth in FY25 on the back of planned increased brand investment and distribution.”
Flavio Palumbo, Chief Commercial Officer
About Immuron
Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases. For more information visit: http://www.immuron.com
About PRISM MarketView:
Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on Twitter.
Disclaimer:
PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
Contact:
Prism MarketView | Stock Market News & Investment Opportunities